ABBVIE
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
- Conditions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1884
- Registration Number
- NCT05158894
- Locations
- 🇺🇸
Iqvia /Id# 244683, Durham, North Carolina, United States
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 44
- Registration Number
- NCT05144243
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 232253, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University /ID# 233704, Wenzhou, Zhejiang, China
🇨🇳Duplicate_The Affiliated Hospital of Guizhou Medical University /ID# 232465, Guiyang, China
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 210
- Registration Number
- NCT05139602
- Locations
- 🇺🇸
Skin Care Research Boca Raton /ID# 240758, Boca Raton, Florida, United States
🇺🇸Duplicate_Skin Specialists, PC /ID# 240804, Omaha, Nebraska, United States
🇺🇸Schweiger Dermatology, P.C. /ID# 240900, New York, New York, United States
A Study to Assess Disease Activity in Adolescent and Adult Participants With Atopic Dermatitis Who Receive Oral Upadacitinib Tablets in a Real-World Setting
- Conditions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 772
- Registration Number
- NCT05139836
- Locations
- 🇩🇪
Durani & Durani, Heidelberg,DE /ID# 249172, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪Universitaetsklinik Heidelberg /ID# 245834, Heidelberg, Baden-Wuerttemberg, Germany
🇩🇪Hautarztpraxis Langenau /ID# 242279, Langenau, Baden-Wuerttemberg, Germany
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 292
- Registration Number
- NCT05134649
- Locations
- 🇺🇸
Steve Yoelin MD Medical Assoc. Inc /ID# 232004, Newport Beach, California, United States
🇺🇸Susan H. Weinkle MD /ID# 232001, Bradenton, Florida, United States
🇺🇸Research Institute of the Southeast, LLC /ID# 231974, West Palm Beach, Florida, United States
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1200
- Registration Number
- NCT05127954
- Locations
- 🇺🇸
Pediatrix Medical Group of Florida /ID# 233336, Winter Park, Florida, United States
🇺🇸Centricity Research Columbus /ID# 238832, Columbus, Ohio, United States
🇺🇸Houston Clinical Research Associates /ID# 246522, Houston, Texas, United States
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1059
- Registration Number
- NCT05125302
- Locations
- 🇺🇸
Encore Medical Research /ID# 245682, Hollywood, Florida, United States
🇺🇸Advanced Research Institute of Miami /ID# 230292, Homestead, Florida, United States
🇺🇸Auzmer Research /ID# 239251, Lakeland, Florida, United States
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT05105841
- Locations
- 🇯🇵
National Cancer Center Hospital /ID# 232449, Chuo-ku, Tokyo, Japan
🇯🇵University Hospital Kyoto Prefectural University of Medicine /ID# 239883, Kyoto-shi, Kyoto, Japan
🇯🇵Tohoku University Hospital /ID# 238433, Sendai-shi, Miyagi, Japan
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 16
- Registration Number
- NCT05094050
- Locations
- 🇺🇸
Texas Movement Disorder Specialists /ID# 238607, Georgetown, Texas, United States
🇺🇸The Movement Disorder Clinic of Oklahoma /ID# 238610, Tulsa, Oklahoma, United States
🇺🇸Carolina Phase 1, LLC /ID# 239836, Raleigh, North Carolina, United States
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 352
- Registration Number
- NCT05094128
- Locations
- 🇩🇪
Praxis. F. Bigdeli-Wilshusen /ID# 272904, Hanover, Niedersachsen, Germany
🇩🇪ACURA Rheumazentrum Baden-Bade /ID# 249751, Baden-baden, Baden-Wuerttemberg, Germany
🇩🇪Heilig, Heidelberg, DE /ID# 240492, Heidelberg, Baden-Wuerttemberg, Germany